- GE HealthCare benefits from the trend of onshoring and tariffs associated with the Trump administration.
- The White House threatened new tariffs on Canadian imports, highlighting the healthcare sector's reliance on integrated Canadian supply chains.
- The White House threatened tariffs on Canadian imports, highlighting the healthcare sector's reliance on integrated Canadian supply chains.
FDA approved Moderna's Spikevax for high-risk children amid White House tariff threats on Canadian imports.
1 report, 1 independent
Updated Jul 15
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA approved Moderna's Spikevax for high-risk children amid White House tariff threats on Canadian imports.
Who's involved
What this event is mainly aboutKeep exploring
Part of
The White House threatened tariffs on Canadian imports, highlighting the healthcare sector's reliance on integrated Canadian supply chains.Also in this story
- Healthcare companies, including UnitedHealth Group, face market decline due to trade tensions and tariff threats on Canadian imports.
- Tariff imposition targets goods from Canada, affecting companies like LiveRamp under the Trump administration's policy.
- The White House announced new tariffs on Canadian imports while noting integrated supply chains and drug price headwinds affecting the healthcare sector.
The entities involved
- FDA
-
Moderna
American biotechnology company
- White House
Related events
- FDA approved new COVID booster vaccines, with major medical groups like AAP and AMA offering support and facing political pressure regarding their guidance.
- Unregulated products are bypassing official government approval processes.
- The FDA authorized drug use in New Mexico and Texas, while the Trump administration faced criticism over trade decisions.
- BioXcel Therapeutics received FDA approval for its drug and announced results from New Haven.
- A product was launched in the U.S. market following FDA involvement.
Coverage
Newest first; wire copies grouped- StockStoryWhy Moderna (MRNA) Stock Is Falling Today Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.6% in the morning session after JPMorgan added the stock to its list of top short ideas for the